Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 3Triple Negative Breast Neoplasms 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Neoplasm Metastasis 2Carcinoma, Non-Small-Cell Lung 2Peritoneal Neoplasms 1Ovarian Neoplasms 1Metastatic Adenocarcinoma of the Pancreas 1Fallopian Tube Neoplasms 1Carcinoma 1

Interventions

trastuzumab deruxtecan 4eribulin 3Capecitabine 3Trastuzumab 2Paclitaxel 2Gemcitabine 2Carboplatin 2130-nm albumin-bound paclitaxel 2telisotuzumab vedotin 1taxane 1pertuzumab 1pembrolizumab 1osimertinib 1olaparib 1margetuximab 1exemestane 1entrectinib 1encorafenib 1dacomitinib 1capmatinib 1binimetinib 1adagrasib 1abemaciclib 1Vinorelbine 1Vemurafenib 1Pemetrexed 1Imlunestrant 1Gefitinib 1Fulvestrant 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has announcements × Neoplasm Metastasis × 130-nm albumin-bound paclitaxel × Clear all
NCT05374512 2026-05-15

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

AstraZeneca

Phase 3 Active not recruiting
644 enrolled 1 FDA
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT03734029 2025-10-06

Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

Daiichi Sankyo

Phase 3 Active not recruiting
557 enrolled 22 charts 1 FDA
Breast

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡